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Clinical Question
Is measurement of apolipoproteins better 
than traditional lipid measurements for 
predicting cardiovascular risk?
Evidence-Based Answer
Measurement of apolipoprotein B and apo-
lipoprotein A-I is no better than traditional 
lipid measurements and should not be used 
to predict cardiovascular risk. (Strength of 
Recommendation: B, based on meta-analyses 
with conflicting results.) Apolipoprotein B 
and non–high-density lipoprotein choles-
terol (HDL-C) predict cardiovascular risk 
slightly better than low-density lipoprotein 
cholesterol. Elevated levels of apolipopro-
tein A-I predict a lower risk of cardiovascu-
lar events except stroke, but not as well as 
elevated HDL-C levels. 
Evidence Summary
Apolipoproteins are structural components 
of lipoproteins and have a role in receptor 
binding and enzyme activation. Apolipopro-
tein B is carried on all proatherogenic lipo-
proteins in a 1:1 ratio, and apolipoprotein 
A-I is found on nearly all HDL particles.1
High levels of apolipoprotein B predict 
cardiovascular risk about as well as non–
HDL-C. A 2012 meta-analysis pooled data 
from prospective cohort studies of patients 
without baseline cardiovascular disease and 
found that non–HDL-C and apolipoprotein B 
levels were similarly predictive of fatal and 
nonfatal cardiovascular events2 (Table 1 2-4). 
Using a clinical model, the authors calcu-
lated that substituting total cholesterol and 
HDL-C measurements with apolipoprotein 
A-I and B measurements diminished risk 
prediction by 1% (95% confidence interval 
[CI], 0.2% to 1.9%), whereas adding them 
did not significantly improve risk classifi-
cation. A 2011 meta-analysis of prospec-
tive cohort and case-control studies found 
that apolipoprotein B was a slightly better 
predictor of cardiovascular risk than non–
HDL-C, and both were superior to low-
density lipoprotein cholesterol.3 
Among patients receiving statins, mea-
surement of apolipoprotein B is comparable 
to that of non–HDL-C. A 2012 meta-analysis 
of randomized controlled trials of patients 
on statin therapy found that time to the first 
major cardiovascular event was most strongly 
associated with non–HDL-C levels, followed 
by apolipoprotein B and low-density lipo-
protein cholesterol levels.4 The differences 
between hazard ratios were small but statis-
tically significant (P = .002 for non–HDL-C 
vs. low-density lipoprotein cholesterol, and 
P = .02 for non–HDL-C vs. apolipoprotein B).
The benefits of measuring apolipoprotein B 
include the ability to use serum from non-
fasting patients, standardization, and direct 
measurement compared with the calculated 
measurement of low-density lipoprotein 
cholesterol, which may be inaccurate in 
patients with hypertriglyceridemia.5,6
Elevated apolipoprotein A-I levels predict 
coronary events except stroke, but not as well 
as elevated HDL-C levels. Apolipoprotein A-I 
levels are inversely associated with cardio-
vascular disease. In the 2012 meta-analysis 
discussed previously, comparable inverse 
associations for cardiovascular risk were seen 
with HDL-C and apolipoprotein A-I mea-
surements.2 A 2011 prospective cohort study 
of healthy women found an inverse relation-
ship between apolipoprotein A-I levels and 
the incidence of stroke and coronary events 
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(myocardial infarction, coronary revascularization, or 
coronary death).7 Participants included health care pro-
fessionals 45 years and older who were not receiving lipid-
lowering therapy and had a low risk of cardiovascular 
disease. They were grouped into quintiles based on apo-
lipoprotein A-I or HDL-C levels. The average follow-up 
was 11.1 years. There were 319 strokes and 602 coronary 
events among the 26,881 women. Lower apolipoprotein 
A-I and HDL-C levels were associated with a higher risk 
of coronary events except stroke. However, in all quin-
tiles the coronary event association with apolipoprotein 
A-I was weaker than that of HDL-C (hazard ratio for 
apolipoprotein A-I [lowest vs. highest quintiles] = 1.58 
[95% CI, 1.14 to 2.20]; hazard ratio for HDL-C [lowest 
vs. highest quintiles] = 2.19 [95% CI, 1.51 to 3.19]).7
Recommendations from Others
The American College of Cardiology Foundation/ 
American Heart Association and the National Academy 
of Clinical Biochemistry recommend against measure-
ment of apolipoproteins or any additional lipid param-
eters beyond a standard fasting lipid panel for global 
cardiovascular risk assessment.8,9 
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Table 1. Summary of Meta-analyses Comparing Apolipoproteins vs. Traditional Lipid Measurements 
for Predicting Adverse Cardiovascular Events
Number and type  
of studies Outcomes measured
Adverse  
events Biomarker measured
Risk of elevated biomarker  
(95% CI)
26 prospective 
cohort trials  
(N = 139,581)2
Fatal and nonfatal coronary artery 
disease and stroke
12,234 Non–HDL-C HR = 1.27 (1.22 to 1.33)*
Apolipoprotein B HR = 1.24 (1.19 to 1.29)*
Apolipoprotein A-I HR = 0.87 (0.84 to 0.90)*
HDL-C HR = 0.83 (0.78 to 0.87)*
12 (8 prospective 
cohort and case-
control studies;  
N = 233,455)3
Fatal and nonfatal ischemic 
cardiovascular events
22,950 Apolipoprotein B RR = 1.43 (1.35 to 1.51)†
Non–HDL-C RR = 1.34 (1.24 to 1.44)†
Low-density lipoprotein 
cholesterol
RR = 1.25 (1.18 to 1.33)†
8 randomized 
controlled trials  
(N = 38,153)4
Fatal or nonfatal myocardial infarction, 
fatal coronary artery disease, 
hospitalization for unstable angina, 
and fatal or nonfatal stroke at 1 year
6,286 Non–HDL-C HR = 1.16 (1.12 to 1.19)*
Apolipoprotein B HR = 1.14 (1.11 to 1.18)*
Low-density lipoprotein 
cholesterol
HR = 1.13 (1.10 to 1.17)*
CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; HR = hazard ratio; RR = relative risk.
*—HR is calculated as the increased or decreased risk of an adverse event per standard deviation increase in the biomarker.
†—RR is calculated as the increased risk of an adverse event per standard deviation increase in the biomarker.
Information from references 2 through 4.
